Beclometason

Quick links to important sections

Beclometason

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beclometason

Quick Facts

Property Description
Active ingredient Beclometasone dipropionate (Prodrug)
Form Inhaler, Nasal Spray, Cream, Ointment
Pharmacological class Corticosteroid (Glucocorticoid)
Origin Synthetic (Halogenated steroid)
General Purpose To reduce inflammation and suppress immune responses

What is Beclometasone? Understanding Its Identity and Type

Beclometasone, also known by the synonym Beclomethasone, is a synthetic corticosteroid that is specifically classified within the pharmacological class of Glucocorticoids. As a synthetic medication, it is chemically derived to possess potent anti-inflammatory and immunomodulating properties. The primary active ingredient administered is often the prodrug form, Beclometasone dipropionate, which is subsequently converted by the body into the more active metabolite, Beclometasone-17-monopropionate, to maximize therapeutic effect. This complex metabolic process ensures a highly localized anti-inflammatory action at the site of application, a characteristic that is clinically recognized for differentiating it from older, systemically active steroids.

How is Beclometasone Classified and What is Its General Purpose?

Its official classification as an anti-inflammatory agent means Beclometasone’s general purpose is to control and suppress excessive immune responses and inflammation in targeted tissues. The medication functions as a glucocorticoid receptor agonist, and this physiological action allows it to effectively reduce swelling and irritation by limiting the production of inflammatory chemical messengers in the cells. This capability positions Beclometasone as a foundation for prophylactic therapy, typically intended for chronic conditions requiring sustained inflammation control, like long-term respiratory management. While often utilized as a single-active-ingredient product, it is also integrated into fixed combination formulations for specialized management, maintaining its core anti-inflammatory role.

Dosage Forms: Where and How Beclometasone is Used

Beclometasone is manufactured into several dosage forms optimized for targeted application, ensuring the active ingredient acts where it is needed most. These preparations include aerosol liquids within a pressurized metered-dose inhaler and dry powder inhaler systems, an aqueous nasal spray for direct intranasal use, and cream or ointment bases for dermatological application. Correspondingly, the main routes of administration are inhalation (oral), intranasal, and topical. Its positioning is often for both adult and pediatric patient groups (typically age 5 and older for some forms), allowing the potent synthetic corticosteroid to be delivered directly to the tissue requiring treatment, whether it is the lungs, the nasal lining, or the skin, promoting focused therapeutic action.

Regulatory References

  1. WHO Essential Medicines List Entry for Beclometasone

What side effects are possible with Beclometason?

Possible side effects and safety information

The official safety profile for Beclometasone dipropionate is structured to differentiate between common localized reactions and less frequent but more serious systemic effects, based on regulatory classifications.

Frequency-Classified Adverse Reactions

The most frequently documented reactions are typically localized to the administration site. Common adverse reactions for inhaled formulations include headache, pharyngitis, and sinusitis. For the intranasal route, nasal discomfort and epistaxis (nosebleeds) are commonly listed. The frequency classifications are derived from regulatory documents based on incidence in clinical trials.


Serious Adverse Reactions and Systemic Concerns

Beclometasone is a glucocorticoid, and its systemic effects are categorized by System-Organ Class. Serious adverse reactions highlighted in official labeling include paradoxical bronchospasm, which may occur immediately after administration. Systemic effects, such as adrenal suppression (HPA axis effects), hypercorticism, and potential decrease in bone mineral density, are noted, particularly with high dosages prescribed for long periods.


Population and Usage Restrictions

Specific safety considerations are noted for certain populations. The potential for growth retardation requires the routine monitoring of pediatric patients. Furthermore, Glaucoma and Cataracts are identified as potential adverse reactions associated with the use of Beclometasone. Use is officially restricted in cases of known hypersensitivity and should be avoided in patients with recent nasal surgery or trauma until healing is complete.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented overdose profile for Beclometasone primarily relates to the consequences of chronic use of excessive doses leading to systemic exposure, rather than acute toxicity. As a potent corticosteroid, the main physiological manifestation of overexposure is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, where the body's natural hormone production is reduced.

Documented Manifestations and Severe Outcomes

Classification Manifestations and Effects
Chronic Overdose Signs Cushingoid features and manifestations of adrenal suppression.
Severe Outcome Adrenal crisis, which is a severe, potentially life-threatening complication associated with HPA axis suppression.
Pediatric Consideration Pediatric patients may demonstrate greater susceptibility to HPA axis suppression and resulting signs like linear growth retardation.

Emergency Actions Mandated by Regulators

Regulators mandate that individuals seek immediate medical attention upon the suspicion or presentation of signs consistent with acute adrenal suppression or Adrenal crisis. Management procedures documented in labeling include symptomatic and supportive treatment and require monitoring of the HPA axis function for recovery. No specific antidote is known for this type of overdosage.

Therapeutic Uses of Beclometason

Beclometasone is applied across multiple domains where chronic inflammation leads to symptoms that interfere with daily functioning. The medication’s therapeutic use is broadly recognized. It may assist with managing groups of symptoms that may appear suddenly or intensify over time, providing support during difficult episodes by easing distress.

The medication is commonly used to help with conditions involving inflammatory or irritative states, including the long-term management of persistent asthma, relief from allergic rhinitis (seasonal and perennial), and the topical management of steroid-responsive inflammatory skin disorders like eczema and psoriasis. Beclometasone is used as a controller medication for these conditions, with the primary benefit being that it supports the management of recurring symptoms and helps maintain a sense of stability when symptoms are more noticeable.

Quick Therapeutic Focus

Quick Fact: Relief for Inflammatory Symptoms
Primary Focus Symptom management and maintenance
Focus Area Conditions characterized by periods of heightened symptoms
Key Benefit Helps improve day-to-day comfort during symptomatic periods

Eligibility and Restrictions for Use

Who Can and Cannot Use Beclometason?

The official eligibility profile for Beclometasone is defined by absolute contraindications, age-based limits, and conditional use requirements, all strictly outlined in government regulatory labeling.

Eligibility Scope Official Regulatory Classification
Populations Contraindicated Must not be used in patients with a known hypersensitivity to the drug or any component of the formulation. Also prohibited for the primary treatment of status asthmaticus or acute asthma attacks [FDA/EMA].
Age-Related Eligibility Adults and adolescents are eligible for use across most forms. Inhaled Beclometasone is typically indicated for patients 5 years of age and older. Use in children under this minimum age is often not recommended as efficacy and safety have not been established [FDA].
Conditional Use Restrictions Caution is advised for patients with active or quiescent infections, including tuberculosis or ocular herpes simplex, as corticosteroid use may worsen these conditions [NIH]. Restricted use applies to patients transferring from systemic (oral) steroids due to the risk of impaired adrenal function.
Pregnancy and Lactation Status Pregnancy: Use is considered restricted and advised only if the potential benefit justifies the potential risk. Lactation: Caution is advised, as the substance is assumed to be excreted into human milk [LactMed].

Connection to the overall eligibility profile: Regulatory documents establish clear boundaries for Beclometasone use, mandating absolute non-eligibility for hypersensitive patients and those experiencing acute respiratory crises. Use is also limited by a minimum established age and requires conditional medical assessment in the presence of certain infectious comorbidities, strictly defining who can and cannot use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Beclometasone, focusing on metabolic effects and additive pharmacological actions.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with strong CYP3A4 inhibitors, such as Ritonavir or Cobicistat, is officially documented as potentially increasing the systemic exposure to the active Beclometasone metabolite. This pharmacokinetic interaction is a key area of caution outlined in regulatory labels.

In terms of pharmacodynamics, using Beclometasone concurrently with other steroid-containing medicines (including creams, tablets, or other inhalers) may lead to a cumulative, additive effect. This is documented to increase the potential for systemic glucocorticoid effects.

Product Formulation and Procedural Constraints

Interaction-related restrictions exist for specific product formats. Certain Beclometasone inhaler brands contain ethanol (alcohol) excipients, which creates an interaction risk with medicines like Disulfiram and Metronidazole. For Beclometasone-containing fixed combination medicinal products, a mandatory separation of at least 12 hours is required before the administration of halogenated anaesthetics due to associated risks noted in prescribing information. Regulatory sources also note a lack of specific safety testing regarding co-administration with herbal remedies and supplements.

Mechanism of Action

Beclometasone mechanism of action is mediated through the modulation of genetic expression by an intracellular process. The parent compound, Beclometasone dipropionate, functions as a prodrug, which is quickly converted by esterase enzymes into the active molecule, Beclometasone-17-monopropionate (17-BMP), upon reaching the target tissue.

Targeting the Glucocorticoid Receptor

The active metabolite, 17-BMP, functions as an agonist by binding to the Glucocorticoid Receptor (GR) found inside cells. This binding creates a complex that translocates into the cell nucleus, initiating the mechanism's control over the cell's genetic processes. This molecular control over gene expression results in the broad modulation of inflammatory pathways.


Dual Gene Control: Suppression and Activation

Once in the nucleus, the GR complex performs a dual function: it silences the genes responsible for producing pro-inflammatory chemicals by inhibiting transcription factors (like NF-kappa B), while simultaneously activating genes that synthesize natural anti-inflammatory proteins. This cellular control results in a reduction in the creation of key inflammatory mediators, such as prostaglandins, leukotrienes, and cytokines, which attenuates the inflammatory signal.


Reducing Cellular Infiltration and Edema

The cumulative effect of this molecular action addresses the cellular changes associated with chronic inflammatory states. By reducing the local concentration of inflammatory chemicals and suppressing the migration and activity of immune cells (like eosinophils), the drug supports localized vasoconstriction and decreases capillary permeability. This action reduces fluid leakage into the tissue and attenuates tissue edema.

Dosage and Administration Information

How to Use Beclometasone: Official Administration Guidelines

Beclometasone dipropionate is primarily administered via oral inhalation for the long-term management of asthma and intranasal route for allergic rhinitis symptoms. The medication is designated for scheduled maintenance use at fixed intervals and is not intended for intermittent or as-needed dosing. The general principle of usage is to titrate the dose to the lowest effective level once stable control is achieved.


Standard Dosing and Frequency

Official dosing is determined by the administration route and patient age:

Indication Administration Route Typical Frequency Maximum Daily Dose (Adults 12 years)
Asthma Oral Inhalation Twice Daily (BID) 640 mu g
Allergic Rhinitis Intranasal Once or Twice Daily 320 mu g

For pediatric patients (4 to 11 years) using the inhaled form for asthma, the total maximum daily dose is generally restricted to 160 mu g. Continuous, daily use is necessary, and therapeutic effects are typically observed within one to four weeks after starting the scheduled regimen.


Procedural Administration Constraints

Specific procedural rules must be followed to ensure proper use:

  1. Priming the device with a specified number of test sprays is required before first use or after a period of non-use to ensure consistent dose delivery.
  2. Following oral inhalation, patients must rinse their mouth with water and spit it out immediately to manage local drug residue.
  3. If a dose is missed, it should be taken as soon as remembered, but two doses must never be taken simultaneously to compensate for the missed dose.
  4. Certain inhalation devices are designed to be used without a spacer or volume holding chamber, requiring adherence to the device’s specific operating instructions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Beclometasone

The research record for Beclometasone dipropionate is described across a wide scientific landscape involving numerous Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. The findings summarized in regulatory and scientific publications describe the types of measurements taken in specific patient populations for each use studied.


Evidence for Use in Persistent Asthma (Inhaled)

The research base for inhaled Beclometasone was studied in the context of persistent asthma, a condition characterized by fluctuating or episodic manifestations. Studies explored how this medicine was evaluated in patients compared to an inactive substance (placebo) or other similar treatments. Researchers primarily examined outcomes related to functional imbalance, specifically measuring changes in lung function (like FEV1 and PEFR) and assessing outcomes capturing phases of heightened symptom activity, such as the frequency of asthma episodes (exacerbations) and reported patterns of rescue medication use.

Studies reported measurements of lung function changes and patterns in overall symptom experience among individuals in the Beclometasone groups. However, systematic reviews have noted that while the research contributes to understanding symptom patterns, findings were mixed across studies regarding a consistent dose-response relationship for all measured outcomes.


Evidence for Use in Allergic Rhinitis (Nasal Spray)

The nasal spray formulation was studied for conditions involving periods of heightened symptoms such as Seasonal and Perennial Allergic Rhinitis. The evidence is derived from controlled studies, including RCTs. These research efforts primarily monitored outcomes related to physical discomfort, specifically using the Total Nasal Symptom Score (TNSS). Research examined how these patient-reported outcomes describing perceived discomfort changed when the medicine was evaluated in adolescents, adults, and children as young as 4 years.


What is Still Uncertain About Beclometasone

Evidence highlights what is known—and what is still uncertain—about this medicine. For both inhaled and nasal use, research indicates that a consistently clear relationship between dosage and measured outcomes findings were mixed; meaning that small changes in dose may not reliably lead to predictable differences in all symptom patterns. Furthermore, the applicability of findings to patients with multiple concurrent health issues remains insufficient, as the results apply only to the populations studied.

Key Studies & References

  1. Beclomethasone Dipropionate Delivered by Nebulizer in Children With Persistent Asthma (Clinical Trial NCT00497523)
  2. Study of the Pharmacodynamics and Pharmacokinetics of Nasal Aerosols in Allergic Rhinitis (Clinical Trial NCT02646904)

Frequently Asked Questions (FAQ)

Common questions about Beclometason (FAQ)


Q: How quickly should I expect Beclometason to start working?

A: Symptom relief is generally described as requiring continuous therapy for several days or weeks. Official product information indicates that the full therapeutic effects are typically observed within one to four weeks after the scheduled regimen is started.

Q: What happens if I forget a dose of Beclometason?

A: Regulatory guidance describes that a missed dose may be taken as soon as it is remembered. However, it is explicitly advised that two doses must never be taken simultaneously to compensate for the one that was missed.

Q: Is Beclometason the same as Budesonide or Fluticasone?

A: Beclometasone is classified as a glucocorticoid, placing it in the same therapeutic class as medicines like Budesonide and Fluticasone. These are all types of inhaled corticosteroids used to manage inflammation.

Q: Is Beclometason safe to use during pregnancy?

A: The official safety classification regarding use during pregnancy varies by source (for example, it is listed as Category B3 in Australia). Official guidance indicates that use during pregnancy involves weighing potential benefits against potential risks, which is a consideration for healthcare professionals.

Q: What are the most common side effects reported for Beclometason?

A: According to official documentation, common local side effects for the nasal spray may include a headache, irritation inside the nose, sneezing, nosebleed, or an unpleasant taste or smell. For the inhaled form, common local effects include hoarseness, cough, and throat irritation, as well as the potential for oral thrush (candidiasis). This is often observed with local administration.

Q: Can Beclometason cause weight gain?

A: Weight gain is a reported systemic side effect associated with glucocorticoids in general. Official documents note this as a potential symptom of systemic exposure that may occur, particularly with very high dosages.

Q: Are there any long-term risks associated with using Beclometason?

A: Regulatory documents describe that long-term use, especially at high doses, may be associated with systemic effects throughout the body. These documented risks include the potential for systemic effects such as adrenal suppression, decreased bone mineral density, and the development of cataracts or glaucoma.

Q: Does Beclometason affect your sleep?

A: Although rare, the systemic effects of corticosteroids can sometimes lead to psychological or behavioral changes. Official patient information notes that these effects may include problems with sleeping, anxiety, or nervousness.

Q: Does Beclometason affect bone density?

A: Official information indicates the potential for decreased bone mineral density with prolonged use of high doses. This is a systemic effect noted in regulatory documents.

Q: Is it normal to feel a change in taste after using Beclometason?

A: Yes, a change in taste, described as an unpleasant taste or smell, has been reported as a common side effect in official patient information, particularly with the nasal spray formulation.

Q: Can Beclometason cause throat irritation or hoarseness?

A: Yes, official documents indicate that the inhaled form of the medicine may commonly cause local issues such as throat irritation and hoarseness. This is due to the local effect of the drug during administration.

Q: Does Beclometason have a 'rebound' effect if you stop using it?

A: Official guidance advises that the medicine should not be stopped abruptly without consulting a healthcare professional. Abrupt cessation could potentially lead to the return or exacerbation of the condition being treated.

Q: Is there a maximum amount of time someone can safely use Beclometason?

A: While the duration of use is generally described as 'as long as required' for control of the condition, regulatory documents recommend that a physician periodically re-evaluate the patient’s dosage to ensure the lowest effective dose is maintained after 2 to 3 months of use.

Q: Can Beclometason cause issues with vision or cataracts?

A: Official warnings note that systemic effects, especially with long-term use of high doses, include the potential for developing cataracts and glaucoma (vision problems related to eye pressure).

Q: Is Beclometason ever prescribed for skin conditions?

A: Yes, besides the inhaled and nasal forms, Beclometasone dipropionate is also officially available in topical formulations, such as ointments or creams, which are used for treating certain inflammatory skin conditions (dermatoses).

Q: How often do people experience a specific side effect like headache with Beclometason?

A: Headache is frequently listed as a common side effect in official adverse reaction tables. This generally means it may affect between 1 in 10 and 1 in 100 people using the medicine.

Q: Can using Beclometason make you more susceptible to colds or flu?

A: Regulatory documentation states that corticosteroids can suppress the immune system. Official warnings advise that this can potentially increase the risk of developing serious infections, such as chickenpox or measles, if a patient is not immune.

Q: What should I do if my symptoms get worse while using Beclometason?

A: Official patient guidance emphasizes that if symptoms worsen, or if the short-acting reliever medicine becomes less effective, patients are instructed to seek medical attention. This review is generally performed to assess the maintenance therapy regimen.

Q: Does Beclometason contain caffeine?

A: Official excipient lists for Beclometasone formulations do not typically include caffeine. However, regulatory documents do list other components like lactose or ethanol (alcohol) if they are present in a specific product type.

Q: Are there any dietary restrictions mentioned for people using Beclometason?

A: Official guidance advises patients to discuss the use of the medicine with food, alcohol, or tobacco with a healthcare professional. There are, however, no universally defined, specific dietary restrictions listed on most drug labels.

Q: Can people with high blood pressure use Beclometason?

A: Regulatory documents advise that patients with existing heart problems, including high blood pressure, should use the medication with caution. Regulatory documents indicate that monitoring by a healthcare professional may be appropriate for patients with these conditions.

Q: Is Beclometason a controlled substance?

A: No, official regulatory classifications in the US and UK indicate that Beclometasone is not classified as a controlled substance. It is typically sold as a prescription-only medicine.

Q: What should I do if I accidentally swallow some Beclometason from a nasal spray?

A: According to patient information, accidentally swallowing a small amount of the nasal spray or using too much is unlikely to be harmful. If there is concern, regulatory advice suggests contacting a healthcare professional.

Q: Can Beclometason affect blood sugar levels?

A: As a glucocorticoid, Beclometasone has the potential to cause systemic effects. Official product information notes that it can increase blood sugar, and patients with diabetes may require careful monitoring.

Q: Is there a generic version of Beclometason available?

A: Official product listings and drug databases show that different manufacturers distribute products under the Beclometasone dipropionate generic name. This indicates that generic versions are available alongside branded formulations.

Q: What are the official recommendations regarding driving or operating machinery while using Beclometason?

A: Official patient information often states that using Beclometason is not likely to affect a person's ability to drive, operate tools, or use machinery.

Q: What does evidence say about using Beclometason for seasonal allergies?

A: Official research summaries group the results under the general indication of Allergic Rhinitis. Evidence for the nasal spray has been derived from controlled studies examining both seasonal and perennial forms of the condition.

Q: Is Beclometason a common trigger for allergic reactions itself?

A: Hypersensitivity reactions have been reported after the drug's administration. These reactions, which may include rash, hives, or swelling of the face, lips, tongue, or throat, are described as requiring immediate medical attention.

Q: Are there any official reports of dependence or withdrawal with Beclometason?

A: Official warnings focus on the risk of systemic effects that can affect the body's natural steroid production (HPA axis suppression) with high-dose, long-term use. Abrupt cessation of systemic steroids (if used concurrently) may cause an exacerbation of allergic diseases.

Q: What does the FDA documentation say about Beclometason and immune system function?

A: FDA and other documentation note that corticosteroids can suppress the immune system. This mechanism can potentially worsen certain existing infections and increase the risk of serious disease from infections like chickenpox or measles.

Q: What is the difference between Beclometason dipropionate and just Beclometason?

A: Beclometasone dipropionate is officially described as a prodrug. This means it is an inactive compound that is quickly converted by the body into the active molecule, Beclometasone-17-monopropionate (17-BMP), which is the compound that produces the anti-inflammatory effect.

How should Beclometason be stored and disposed of?

Storage Conditions

Beclometasone must be stored according to regulatory requirements to maintain its stability and effectiveness.

Storage Requirement Official Condition
Temperature Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Do not freeze. Protect from excessive heat and moisture. Pressurized canisters must not be stored near heat or open flame.
Container Keep medication in the container it came in and ensure it remains tightly closed.
Child Safety Must be stored out of the sight and reach of children in a secure location.

Disposal and Stability

Specific rules govern when the product must be discarded and how it must be disposed of.

  • Discarding the Product: The medicine must be discarded after the number of actuations or sprays specified on the label has been used, or after the expiration date is reached.
  • Disposal Instructions: Unused or expired Beclometasone must be disposed of according to local pharmaceutical waste requirements.
  • Environmental Rule: The product should not be thrown into household trash or wastewater unless specifically directed by a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Beclometason found in:

A-Z Index: